Home Featured Page 3

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Weekly Psychedelic Policy Briefing – August 2, 2026

Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without...

Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at...

Psychedelic Policy Briefing: Week of July 27th, 2026

Beyond the Biological Baseline: Dr. Grace Blest-Hopley on Developing Female-Inclusive Psychedelic...

Q1 2026: Oregon Psilocybin Services Update

Psychedelic Funding Update: Q2 2026

Five Phases, Eight Circuits: Chinese Medicine as a Map for Psychedelic...

Rachel Turetzky, PhD & Douglas S. Wingate, DTCM: The Eight-Circuit Model,...

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Weekly Psychedelic Policy Briefing – August 2, 2026

Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without...

Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at...

Psychedelic Policy Briefing: Week of July 27th, 2026

Beyond the Biological Baseline: Dr. Grace Blest-Hopley on Developing Female-Inclusive Psychedelic...

Q1 2026: Oregon Psilocybin Services Update

Psychedelic Funding Update: Q2 2026

Five Phases, Eight Circuits: Chinese Medicine as a Map for Psychedelic...

Rachel Turetzky, PhD & Douglas S. Wingate, DTCM: The Eight-Circuit Model,...

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY